Venous thromboembolism in the patient with cancer

Cancer

Volumn 117, Issue 7, 2011, Pages 1334-1349

  Lyman, Gary H ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

anticoagulant; cancer; chemotherapy; low molecular weight heparin (LMWH); thromboprophylaxis; venous thromboembolism (VTE)

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; BEMIPARIN; BEVACIZUMAB; CERTOPARIN; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RIVAROXABAN; SEMULOPARIN; THALIDOMIDE; TINZAPARIN; WARFARIN;

BLEEDING; BRAIN CANCER; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DISEASE COURSE; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG EMBOLISM; LYMPHOMA; MEDICAL SOCIETY; METASTASIS; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PANCREAS CANCER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 79952824034     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25714     Document Type: Review

References (88)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH., Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5: 632-634. (Pubitemid 46680709)
2. Lyman GH, Khorana AA., Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009; 27: 4821-4826.
3. Lee AY., Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2005; 128: 291-302. (Pubitemid 40216150)
4. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25: 5490-5505. (Pubitemid 350232226)
5. Gao S, Escalante C., Venous thromboembolism and malignancy. Expert Rev Anticancer Ther. 2004; 4: 303-320. (Pubitemid 38477344)
6. Khorana AA,. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009; 20: 1619-1630.
7. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100: 3484-3488. (Pubitemid 35303914)
8. Lee AY., Cancer and venous thromboembolism: prevention, treatment and survival. J Thromb Thrombolysis. 2008; 25: 33-36.
9. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164: 1653-1661. (Pubitemid 39037944)
10. Dobesh PP., Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009; 29: 943-953.
11. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH., Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24: 484-490. (Pubitemid 46630468)
12. Chew HK, Wun T, Harvey D, Zhou H, White RH., Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166: 458-464.
13. Chew HK, Wun T, Harvey DJ, Zhou H, White RH., Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007; 25: 70-76. (Pubitemid 350003053)
14. Khorana AA, Rao MV., Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res. 2007; 120 (suppl 2): S41-S50. (Pubitemid 350103848)
15. Behranwala KA, Williamson RC., Cancer-associated venous thrombosis in the surgical setting. Ann Surg. 2009; 249: 366-375.
16. Osborne NH, Wakefield TW, Henke PK., Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol. 2008; 15: 3567-3578.
17. Rao MV, Francis CW, Khorana AA,. Who′s at risk for thrombosis? Approaches to risk stratifying cancer patients. In:, Khorana AA, Francis CW, eds. Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention, and Treatment. New York, NY: Informa Healthcare USA, Inc; 2007: 169-192.
18. Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006; 47: 1029-1033.
19. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006; 24: 1112-1118. (Pubitemid 46638808)
20. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH., Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110: 2339-2346. (Pubitemid 350100757)
21. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE., Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006; 119: 60-68. (Pubitemid 43117468)
22. Gray KN, Chu D, Wu S, Lin RZ., Risk of venous thromboembolism with thalidomide in cancer patients: a systematic review and meta-analysis of randomized controlled trials [abstract]. Blood. 2008; 112:Page. Abstract 3820.
23. Yang X, Brandenburg NA, Freeman J, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009; 29: 161-171.
24. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99: 1232-1239. (Pubitemid 47299901)
25. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S., Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300: 2277-2285.
26. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98: 708-714. (Pubitemid 43821788)
27. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH., Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008; 168: 2377-2381.
28. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW., Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902-4907.
29. Kuderer NM, Khorana AA, Francis CW, et al. Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy [abstract]. Blood. 2008; 112:Page. Abstract 172.
30. Streiff MB, Baird MF, Bennett CL, et al. Venous thromboembolic disease. Available at:. Accessed August 23, 2010.
31. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010; 153: 8-18.
32. De Cicco M, Matovic M, Balestreri L, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann Oncol. 2009; 20: 1936-1942.
33. Young AM, Billingham LJ, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. 2009; 373: 567-574.
34. Weber C, Merminod T, Herrmann FR, Zulian GB., Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer. 2008; 16: 847-852. (Pubitemid 351809800)
35. Robins HI, O′Neill A, Gilbert M, et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol. 2008; 62: 227-233. (Pubitemid 351692078)
36. Niers TM, Di NM, Klerk CP, Baarslag HJ, Buller HR, Biemond BJ., Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost. 2007; 5: 1878-1882. (Pubitemid 47288945)
37. Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W., Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008; 50: 298-303.
38. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007; 95: 507-512. (Pubitemid 46709395)
39. Miller KC, Padmanabhan S, Dimicelli L, et al. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma. 2006; 47: 2339-2343. (Pubitemid 44768427)
40. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J., Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12: 389-396. (Pubitemid 44359237)
41. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F., Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies-a randomized, controlled study. Acta Paediatr. 2006; 95: 1053-1059. (Pubitemid 44385108)
42. Ikhlaque N, Seshadri V, Kathula S, Baumann MA., Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol. 2006; 81: 420-422. (Pubitemid 43787928)
43. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005; 80: 1568-1574. (Pubitemid 41747058)
44. Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2006; 17: 289-296. (Pubitemid 43160120)
45. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005; 23: 4057-4062. (Pubitemid 46211310)
46. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005; 23: 4063-4069. (Pubitemid 46211311)
47. Einstein MH, Kushner DM, Connor JP, et al. A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients. Obstet Gynecol. 2008; 112: 1091-1097.
48. Shukla PJ, Siddachari R, Ahire S, et al. Postoperative deep vein thrombosis in patients with colorectal cancer. Indian J Gastroenterol. 2008; 27: 71-73.
49. Simonneau G, Laporte S, Mismetti P, et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006; 4: 1693-1700. (Pubitemid 44144795)
50. Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009; 95: 129-134.
51. Cini M, Zamagni E, Valdre L, et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol. 2010; 84: 484-492.
52. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10: 943-949.
53. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 23: 2123-2129. (Pubitemid 46218703)
54. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119: 1062-1072. (Pubitemid 44826932)
55. Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009; 37: 349-356.
56. Lyman GH., Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer. 2009; 115: 5637-5650.
57. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997; 84: 1099-1103.
58. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346: 975-980. (Pubitemid 34983247)
59. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793-800. (Pubitemid 29420474)
60. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ., Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110: 874-879. (Pubitemid 39096017)
61. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006; 332: 325-329.
62. Kuderer NM,. Low-molecular-weight heparin for venous thromboprophylaxis in ambulatory cancer patients: a systematic review meta-analysis of randomized controlled trials [abstract]. Presented at the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA.
63. Riess H, Pelzer U, Deutschinoff G, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial [abstract LBA4506]. Presented at: 2009 Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL.
64. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004; 22: 1944-1948. (Pubitemid 41095187)
65. Perry JR, Julian JA, Laperriere J, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010; 8: 1959-1965.
66. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006; 81: 758-767. (Pubitemid 43839491)
67. Maraveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study) [abstract O-6503]. Presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress; September 20-24, 2009; Berlin, Germany.
68. Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer-results of the TOPIC studies [abstract 1707]. Presented at the XX Congress International Society on Thrombosis and Haemostasis; August 6-12, 2005; Sydney, New South Wales, Australia.
69. Cunningham MS, Preston RJ, O′Donnell JS., Does antithrombotic therapy improve survival in cancer patients? Blood Rev. 2009; 23: 129-135.
70. Kuderer NM, Khorana AA, Lyman GH, Francis CW., A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007; 110: 1149-1161. (Pubitemid 47312882)
71. Kuderer NM, Ortel TL, Francis CW., Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009; 27: 4902-4911.
72. Connolly GC, Kuderer NM, Culakova E, Francis CW, Lyman GH, Khorana AA., Leukocytosis, thrombosis and mortality in cancer [abstract OC-TU-018]. Presented at XXII Congress International Society on Thrombosis and Haemostasis; July 11-16, 2009; Boston, MA.
73. Sud R, Khorana AA., Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009; 123 (suppl 4): S18-S21.
74. Khorana AA, Connolly GC., Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009; 27: 4839-4847.
75. Petralia GA, Rickard M, Baginski M, et al. Venous thromboembolism and cancer: the PERCEIVE Registry [abstract P-T-489]. Presented at the XXI Congress International Society on Thrombosis and Haemostasis; July 6-2, 2007; Geneva, Switzerland.
76. Clinicaltrials.gov website. Clinicaltrials.gov Identifier: NCT00876915. A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients. Available at:. Accessed December 22, 2009.
77. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009; 27: 4919-4926.
78. Martinez-Gonzalez J, Vila L, Rodriguez C,. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc Ther. 2008; 6: 793-802.
79. Kakkar VV, Balibrea J, Martinez-Gonzalez J, Prandoni P,. Late breaking clinical trial: a randomized double blind trial to evaluate the efficacy and safety of prolonging the thromboprophylaxis with bemiparin in patients undergoing cancer abdominal or pelvic surgery (The CANBESURE Study) [abstract LB-MO-002]. Presented at the XXII Congress International Society on Thrombosis and Haemostasis; July 11-16, 2009; Boston, MA.
80. Lassen MR, Dahl OE, Mismetti P, Destree D, Turpie AG., AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: a dose-ranging study. J Thromb Haemost. 2009; 7: 566-572.
81. Viskov C, Just M, Laux V, Mourier P, Lorenz M., Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009; 7: 1143-1151.
82. National Institute for Health Research. AVE-5026 for the prevention of venous thromboembolism in patients at risk. National Horizon Scanning Centre. Available at:. Accessed July 14, 2009.
83. Clinicaltrials.gov identifier: NCT00694382. Evaluation of AVE5026 in the prevention of venous thromboembolism in cancer patients undergoing chemotherapy (SAVE-ONCO). US National Institutes of Health. Available at:. Accessed July 21, 2009.
84. Clinicaltrials.gov Identifier: NCT00679588. Evaluation of AVE5026 as compared to enoxaparin for the prevention of venous thromboembolism in patients undergoing major abdominal surgery (SAVE-ABDO). US National Institutes of Health. Available at:. Accessed January 27, 2010.
85. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765-2775. (Pubitemid 351930851)
86. Ageno W., Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert Rev Cardiovasc Ther. 2009; 7: 569-576.
87. Clinicaltrials.gov identifier: NCT00571649. Venous thromboembolic event (VTE) prophylaxis in medically ill patients. US National Institutes of Health. Available at:. Accessed July 22, 2009.
88. Liebman H, Levine MN, Deitchman D, et al. Apixaban in patients with metastatic cancer: a randomized phase II feasibility study [abstract PP-WE-489]. Presented at the XXII Congress International Society on Thrombosis and Haemostasis; July 11-16, 2009; Boston, MA.